SERTAD2 functions as a transcriptional coregulator that modulates E2F-responsive promoter activity, acting as both coactivator and corepressor of E2F1-TFDP1 and E2F4-TFDP1 complexes to regulate E2F-target gene expression 1. The protein exhibits cell cycle-dependent regulation, with expression peaking at the G1/S boundary and undergoing rapid degradation through CRM1-mediated nuclear export followed by 26S proteasome-dependent degradation 1. SERTAD2 promotes lung tumorigenesis through a Rad18-dependent mechanism and is significantly upregulated in lung cancer tissues, correlating with poor prognosis 2. The gene demonstrates broader oncological relevance, serving as a prognostic biomarker across multiple cancer types including pancreatic ductal adenocarcinoma, colorectal cancer, and epithelial ovarian cancer 345. Additionally, SERTAD2 variants show association with pulmonary fibrosis susceptibility, with specific SNPs affecting disease risk through expression regulation 6. The protein also appears relevant in autoimmune conditions, identified as a potential key gene in multiple sclerosis pathogenesis 7. A related long non-coding RNA, lnc-SERTAD2-3, functions as a tumor suppressor in osteosarcoma by competitively binding miR-29c 8.